Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DIURETICS AS FIRST LINE HYPERTENSION THERAPY COULD SAVE $1 BIL

Executive Summary

DIURETICS AS FIRST LINE HYPERTENSION THERAPY COULD SAVE $1 BIL. annually for every 4 mil. patients treated, William Stason, MD, Harvard School of Public Health, suggested in a presentation at the Drug Information Association's March 14-16 conference on cost-benefit analysis in Hilton Head, South Carolina. Noting that approximately $3.8 bil. is currently being spent each year on medications to treat the 40-60 mil. Americans with elevated blood pressure, Stason estimated that by starting a patient on generic diuretics, adding potassium chloride and when necessary an ACE inhibitor, the resulting average cost per year would be about $120. "For captopril [Squibb's Capoten], the average cost would be about $369," he said. "Nationally, this difference would imply a $1 bil. saving for every 4 mil. hypertensives treated." The researcher described potential cost saving treatment stategy for mild to moderate hypertension (diastolic pressure 90-104): "Start with a diuretic unless it is contraindicated. If it is clearly not tolerated, change to a beta blocker or ACE inhibitor. You may change if the quality of life is significantly reduced even though the patient can hang in there with the drug, or in the case of thiazides if the cholesterol or blood sugar increases to a level that is of concern. Finally, one changes or adds a second medication if blood pressure control is inadequate." Stason based his recommendation on the "roughly comparable" blood pressure lowering effects of currently available drug therapies -- diuretics, beta blockers, calcium channel blockers and ACE inhibitors. "In mild hypertension, thiazides and ACE inhibitors as single-drug treatment appear to control, that is lower, diastolic pressure to less than 90 mm of mercury in about 50% of patients," Stason noted. "Beta blockers and calcium channel blockers as first line therapy are somewhat less likely to be effective." The researcher emphasized that choice of therapy is therefore a tradeoff between cost and quality of life. He observed, however, that while concern about drug costs "is being talked about a lot," there has been little evidence to suggest significant progress in this area, "particularly judging from the remarkable sales success of captopril and calcium channel blockers in the last few years." Stason also indicated a need for further clinical information on the use of ACE inhibitors and calcium antagonists as first line therapy. Calling them "very exciting" and "very expensive" agents, Stason said "their appropriate role as initial therapy in hypertension has yet to be fully defined, in my view." SmithKline has sponsored several cost effectiveness studies to support the use of inexpensive diuretics as first line therapy vs. beta blockers and vasodilators.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel